Merck & Co. (MRK) : Davenport Co scooped up 9,414 additional shares in Merck & Co. during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 12, 2016. The investment management firm now holds a total of 1,651,820 shares of Merck & Co. which is valued at $98,365,881.Merck & Co. makes up approximately 1.46% of Davenport Co’s portfolio.
Other Hedge Funds, Including , Fisher Asset Management boosted its stake in MRK in the latest quarter, The investment management firm added 61,110 additional shares and now holds a total of 6,759,345 shares of Merck & Co. which is valued at $402,518,995. Merck & Co. makes up approx 0.77% of Fisher Asset Management’s portfolio.Lvm Capital Management Ltdmi reduced its stake in MRK by selling 300 shares or 2.72% in the most recent quarter. The Hedge Fund company now holds 10,718 shares of MRK which is valued at $636,113. Merck & Co. makes up approx 0.18% of Lvm Capital Management Ltdmi’s portfolio.F&v Capital Management reduced its stake in MRK by selling 1,160 shares or 1.4% in the most recent quarter. The Hedge Fund company now holds 81,580 shares of MRK which is valued at $4,841,773. Merck & Co. makes up approx 3.53% of F&v Capital Management’s portfolio.Foundation Resource Management Inc reduced its stake in MRK by selling 300 shares or 0.05% in the most recent quarter. The Hedge Fund company now holds 657,137 shares of MRK which is valued at $39,001,081. Merck & Co. makes up approx 7.21% of Foundation Resource Management Inc’s portfolio.Bnp Paribas Arbitrage Sa boosted its stake in MRK in the latest quarter, The investment management firm added 23,793 additional shares and now holds a total of 883,353 shares of Merck & Co. which is valued at $52,427,001. Merck & Co. makes up approx 0.23% of Bnp Paribas Arbitrage Sa’s portfolio.
Merck & Co. closed down -0.02 points or -0.03% at $59.63 with 81,62,693 shares getting traded on Friday. Post opening the session at $59.8, the shares hit an intraday low of $59.25 and an intraday high of $59.93 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
On the company’s financial health, Merck & Co. reported $0.89 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on May 5, 2016. Analyst had a consensus of $0.85. The company had revenue of $9312.00 million for the quarter, compared to analysts expectations of $9445.10 million. The company’s revenue was down -1.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.85 EPS.
Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Companys Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Companys animal health products are sold to veterinarians distributors and animal producers.